PMID- 20340011
OWN - NLM
STAT- MEDLINE
DCOM- 20110524
LR  - 20221207
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 213
IP  - 2-3
DP  - 2011 Feb
TI  - Efficacy and safety of escitalopram versus citalopram in major depressive 
      disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
PG  - 639-46
LID - 10.1007/s00213-010-1822-y [doi]
AB  - RATIONALE: S-citalopram (escitalopram) is the very active moiety of citalopram. 
      It has been shown in many studies to be an effective and safe antidepressant for 
      treating major depressive disorder (MDD). OBJECTIVE: The aim of our study was to 
      compare the efficacy and safety of escitalopram vs citalopram in Chinese MDD 
      patients. METHODS: In the double-blind study, 240 MDD patients were randomly 
      assigned to treatment for 6 weeks either with escitalopram (10-20 mg/d) or 
      citalopram (20-40 mg/d). The primary efficacy measurement was the change of 
      17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to 
      the end of study. The secondary efficacy measurements were response and remission 
      rates. The adverse events (AEs) were recorded by the investigator. RESULTS: Two 
      hundred and three (85%) patients completed the trial. The average dose was 13.9 
      mg/d in the escitalopram group and 27.6 mg/d in the citalopram group. No 
      significant differences were found between the two groups in the change in 
      HAMD-17 total score, response, and remission rate. These results were similar in 
      severe MDD patients. No significant differences were found between the two groups 
      in AEs. No serious AEs were observed in this study. CONCLUSIONS: The study 
      suggests that escitalopram 10-20 mg/d are as effective and safe as citalopram 
      20-40 mg/d in the short-term treatment for Chinese MDD patients.
FAU - Ou, Jian-Jun
AU  - Ou JJ
AD  - Mental Health Institute of The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
FAU - Xun, Guang-Lei
AU  - Xun GL
FAU - Wu, Ren-Rong
AU  - Wu RR
FAU - Li, Le-Hua
AU  - Li LH
FAU - Fang, Mao-Sheng
AU  - Fang MS
FAU - Zhang, Hong-Geng
AU  - Zhang HG
FAU - Xie, Shi-Ping
AU  - Xie SP
FAU - Shi, Jian-Guo
AU  - Shi JG
FAU - Du, Bo
AU  - Du B
FAU - Yuan, Xue-Qin
AU  - Yuan XQ
FAU - Zhao, Jing-Ping
AU  - Zhao JP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100326
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Asian People
MH  - China
MH  - Citalopram/administration & dosage/adverse effects/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2010/03/27 06:00
MHDA- 2011/05/25 06:00
CRDT- 2010/03/27 06:00
PHST- 2010/01/11 00:00 [received]
PHST- 2010/02/26 00:00 [accepted]
PHST- 2010/03/27 06:00 [entrez]
PHST- 2010/03/27 06:00 [pubmed]
PHST- 2011/05/25 06:00 [medline]
AID - 10.1007/s00213-010-1822-y [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2011 Feb;213(2-3):639-46. doi: 
      10.1007/s00213-010-1822-y. Epub 2010 Mar 26.